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ABSTRACT
Hepatoblastoma (HB) is the most common type of liver malignancy in children. 
Recent studies suggest that activation of Yes-associated protein (YAP) is a major 
molecular event in HB development, as activated YAP synergizes with mutant β-catenin 
to promote HB formation in mice (YAP/β-catenin). However, how YAP regulates HB 
development remains poorly defined. Similarly, de-regulation of mammalian target of 
rapamycin complex 1 (mTORC1) signaling has been implicated in multiple tumor types, 
but its functional role in HB development is scarcely understood. In the present study, 
we found that mTORC1 is activated in human HB cells and YAP/β-catenin-induced 
mouse HB tumor tissues. mTOR inhibitor MLN0128 significantly inhibits human HB 
cell growth in vitro. Furthermore, ablation of Raptor, the unique subunit of mTORC1, 
strongly delayed YAP/β-catenin-induced HB development in mice. At the molecular 
level, we found that expression of the amino acid transporter SLC38A1 is induced in 
mouse HB tissues, and amino acid deprivation leads to mTORC1 suppression in HB 
cell lines. Silencing of YAP and/or its paralog, transcriptional co-activator with PDZ 
binding motif (TAZ), decreased SLC38A1 expression as well as mTORC1 activation 
in HB cells. Furthermore, a frequent and concomitant upregulation of mTORC1 and 
SLC38A1 was detected in a collection of human HB specimens. Altogether, our study 
demonstrates the key role of mTORC1 in HB development. YAP and TAZ promote HB 
development via inducing SLC38A1 expression, whose upregulation leads to mTORC1 
activation. Targeting mTOR pathway or amino acid transporters may represent novel 
therapeutic strategies for the treatment of human HB.
INTRODUCTION
Hepatoblastoma (HB) is the most common liver 
malignancy in children. HB usually occurs in the first 
3 years of life. The incidence is slowly but steadily 
increasing at a rate of 1.2-1.5 cases/million/year, partly 
due to prematurity and very low birth weight [1, 2]. The 
development of adjuvant, neo-adjuvant chemotherapy as 
well as the new surgical resection methods significantly 
improved the patients’ survival rate in the last decades [3]. 
Despite these significant achievements in HB treatment, 
the prognosis of patients with metastasis and those who are 
at a stage of pretreatment extent of disease (PRETEXT) 
IV remains unfavorable [4]. Thus, novel targeted therapy 
strategies against HB are highly needed. To achieve this 
goal, a better characterization of the molecular genetics 
and signaling pathways underlying HB pathogenesis is 
imperative.
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Using exome sequencing approaches, recent studies 
have identified multiple genetic modifications in human 
HB samples, including gain-of-function mutations of 
CTNNB1 and CAPRIN2, and loss-of-function mutations of 
Axin1 and SPOP [5]. Among them, mutations of CTNNB1 
and CAPRIN2 genes lead to the activation of the canonical 
Wnt pathway, a major driver genetic event promoting 
HB development [6, 7]. Point mutations as well as in-
frame deletions of the exon 3 in CTNNB1 gene have been 
detected in ~80% of human HB patients. These mutations 
lead to stabilization, nuclear localization, and activation 
of β-catenin transcriptional activity, with consequent 
induction of a large number of target genes involved in 
proliferation, survival, migration, and invasion [8, 9]. It 
is important to underline that while β-catenin cascade is 
essential for HB development [10], over-expression of 
either full length, N-terminal deleted mutation (ΔN90), 
or point mutation (S45Y) forms of β-catenin alone is not 
sufficient to promote HB formation in mice. This evidence 
suggests that activation of additional signaling pathways is 
required, and these pathways may synergize with activated 
Wnt/β-catenin cascade to promote HB development [11]. 
In a recent study from our group, we found that Yes-
associated protein (YAP), the transcriptional co-activator 
downstream of the Hippo tumor suppressor pathway, is 
activated in most human HB samples, with coordinated 
activation of YAP and β-catenin being detected in ~80% of 
HB [11]. Importantly, co-expression of activated YAP and 
β-catenin in the mouse liver via hydrodynamic transfection 
led to HB formation in mice [11]. Our study, therefore, 
establishes YAP as a second signal that synergizes with 
β-catenin to promote HB development. However, the 
molecular mechanisms whereby YAP promotes HB 
formation remain unknown. 
The mammalian target of rapamycin (mTOR) 
pathway is a central regulator of tissue growth and 
homeostasis [12]. It is comprised of two multiple 
protein complexes: mTOR complex 1 (mTORC1) and 
2 (mTORC2), with regulatory-associated protein of 
mammalian target of rapamycin (Raptor) and rapamycin-
insensitive companion of mTOR (Rictor) as unique protein 
components for mTORC1 and mTORC2, respectively 
[12]. De-regulation of the mTOR pathway is frequently 
found in human cancers [13], including hepatocellular 
carcinoma (HCC), the most common form of primary 
liver cancer [14, 15]. Temsirolimus, a first generation 
mTOR inhibitor, is approved by the Food and Drug 
Administration (FDA) for the treatment of advanced stage 
renal cell carcinoma [16]. Similarly, targeting the mTOR 
signaling has been considered a promising strategy for the 
treatment of HCC [17]. However, studies on the functional 
contribution of the mTOR pathway to HB development 
are lacking. 
In the present study, we found that mTORC1 is 
activated in human HB cell lines as well as YAP/β-catenin-
induced mouse HB tissues. A key role of mTORC1 in HB 
development was substantiated by subsequent functional 
studies. Mechanistically, we found that YAP induces 
the expression of the amino acid transporter SLC38A1, 
leading to the activation of mTORC1. Therefore, our study 
strongly suggests that mTORC1 is a major signaling event 
downstream of activated YAP along HB development. The 
results obtained also support the further testing of mTOR 
inhibitors for the treatment of human HB.
RESULTS
Activation of mTORC1 in human and mouse 
hepatoblastoma cells
As a first step to study the functional crosstalk 
between YAP and mTORC1 in HB, we analyzed the 
protein levels of β-catenin, YAP, TAZ (a paralog of YAP), 
and members of the mTOR pathway using two human HB 
cell lines, namely Hep293TT and HepG2 cells [18, 19]. 
The SNU449 human HCC cell line that harbors a mutation 
in the Pten tumor suppressor gene (thus displaying a 
constitutively high mTOR activity) was used as positive 
control. Both Hep293TT and HepG2 HB cell lines have 
N-terminal truncated forms of β-catenin, which could 
be readily detected as a lower band by Western blotting 
(Figure 1A). Total and nuclear YAP and TAZ were 
found to be expressed in the three cell lines, supporting 
the activation of the two protooncogenes in these cells 
(Figure 1A and 1C). Activation of mTORC1 in Hep293TT 
and HepG2 cells was evidenced by the elevated levels of 
phosphorylated/activated (p)-mTOR, phosphorylated/
inactivated (p)-4EBP1, phosphorylated/activated (p)-
S6K and phosphorylated/activated (p)-RPS6 (Figure 
1A). Furthermore, levels of mTORC2 targets, including 
phosphorylated (p)-NDRG1 and phosphorylated/activated 
(p)-AKT (S473) were elevated, thus indicating the 
activation of mTORC2 in Hep293TT and HepG2 cells. 
In contrast, levels of PDK1 substrate phosphorylated/
activated (p)-AKT (T308) were very low/undetectable 
by Western blotting in Hep293TT and HepG2 cell 
lines, whereas they were induced in SNU449 HCC cells 
(Figure 1A). Next, we analyzed the expression of these 
pathways in YAP/β-catenin-induced mouse HB tumor 
tissues (Figure 1B-1D). Consistently, truncated β-catenin 
and nuclear YAP and TAZ could be found in mouse HB 
tissues. In addition, levels of p-mTOR, p-S6K, p-RPS6 
and p-4EBP1 were all higher in HB tumor tissues than 
normal liver tissues, supporting the activation of mTORC1 
in YAP/β-catenin-induced HB tumors. 
In summary, these findings indicate the activation of 
mTORC1 in addition to activated Wnt/β-catenin and YAP/
TAZ in human and mouse HB cells.
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The mTOR inhibitor MLN0128 suppresses HB 
cell growth in vitro
Next, we determined whether HB cells are 
sensitive to mTOR inhibitors. For this purpose, we chose 
MLN0128, a second generation mTOR inhibitor [20]. 
Unlike allosteric mTOR inhibitors (such as Rapamaycin), 
which partially inhibit mTORC1, MLN0128 has been 
shown to complete suppress mTORC1 activity as 
indicated by the strong inhibition of p-4EBP1 [20]. 
Importantly, both Hep293TT and HepG2 cells were found 
to be highly sensitive to MLN0128, with an IC50 around 
50nM (Figure 2A). At the molecular level, administration 
of MLN0128 led to an increased inhibition of mTORC1 
targets, including p-mTOR, p-RPS6 and p-4EBP1, in a 
dose-dependent manner (Figure 2B). In the time course 
study, sustained inhibition of p-mTOR, p-S6K, p-RPS6 
and p-4EBP1 was detected when Hep293TT and HepG2 
cells were treated with MLN0128 at 50nM (Figure 2C). 
Furthermore, MLN0128 dramatically decreased cell 
proliferation and increased cell apoptosis in a dose-
dependent manner (Figure 2D and 2E). Consistently, pro-
survival proteins, including Survivin and MCL-1, were 
found to be decreased, whereas the pro-apoptotic protein 
Bak was upregulated in MLN0128 treated HB cell lines. 
Consistent with increased apoptosis, cleaved caspase 3 
levels were highest in Hep293TT and HepG2 cells treated 
with MLN0128 (Figure 2C).
Altogether, the present data indicate that mTOR 
inhibitor MLN0128 suppresses HB cell growth in vitro. 
Figure 1: mTORC1 is activated in human hepatoblastoma (HB) cells and YAP/β-catenin driven HB lesions. A. 
Representative Western blotting of YAP, TAZ, β-catenin as well as proteins from the AKT/mTOR pathway in Hep293TT and HepG2 HB 
cells, and SNU449 HCC cells. B. Representative Western blotting from wild-type (WT) and YAP/β-catenin-induced mouse HB samples. 
C. Nuclear expression of YAP [YAP (n)] and TAZ [TAZ (n)] in the human HB cell lines (upper level) and mouse HB tissues (lower 
level). Histone H3 was used as loading control for nuclear extraction; and β-tubulin as loading control for cytoplasmic extraction. D. 
Immunohistochemistry showing strong upregulation of phosphorylated (p-)/activated RPS6 (a surrogate marker of mTORC1 activation) in 
YAP/β-catenin-induced mouse HB samples. Magnifications: upper level: 100×, scale bar = 200μm; Lower level: 200×, scale bar = 100μm. 
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Figure 2: MLN0128 inhibits HB cell growth via targeting the mTOR pathway. A. IC50 of MLN0128 for HepG2 and Hep293TT 
HB cells. B. Western blotting showing the downregulation of mTORC1 upon various concentrations of MLN0128 treatment in HepG2 
and Hep293TT cell lines. C. Western blotting of mTOR- and apoptosis pathway-related proteins in HepG2 and Hep293TT cells treated 
with MLN0128 at its IC50 concentration. Graph showing D. BrdU incorporation based proliferation analysis and E. relative apoptosis after 
various concentrations of MLN0128 treatment at different time courses (24, 48 and 72 hours) in HepG2 and Hep293TT cell lines. Data are 
presented as mean ± SEM. *** P < 0.001; A. vs control (untreated cells); B. vs DMSO; and C. vs MLN0128 50nM.
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Ablation of Raptor strongly inhibits YAP/β-
catenin-induced HB tumorigenesis in mice
Since Raptor is the unique and functional component 
of mTORC1, we performed Cre/LoxP mediated Raptor 
knockout by hydrodynamic tranfection in Raptorfl/fl mice. 
The study design is similar to what we have published 
previously [21]. In brief, either pT3-EF1a (pT3, empty 
vector control) or pT3-EF1a-Cre (Cre) plasmid was co-
injected with YAPS127A and ΔN90-β-catenin plasmids 
into Raptorfl/fl mice (Figure 3A). Mice were monitored 
and sacrificed when they were moribund or 21.3 weeks 
post injection. All the pT3 treated mice developed a lethal 
burden of liver tumors by 12.3 weeks post injection and 
were euthanized. In striking contrast, all Cre injected mice 
remained healthy until 21.3 weeks post injection (Figure 
3B and Table 1). Upon dissection, within 10 to 12 weeks 
post injection, all pT3 injected mice showed massive liver 
tumors with high liver weight as well as liver/body ratio 
(Figure 3C and 3D). Histologically, tumor cells resembled 
fetal or crowded fetal subtype of human HB, characterized 
by small cell size as well as small round or oval nuclei 
[11]. Tumor cells were highly proliferative, as indicated 
by Ki67 staining. At this time point, all Cre injected mice 
showed the absence of tumor lesions on the liver surface, 
with normal liver weight and liver/body ratio (Figure 
3C and 3D). Histological examination revealed that the 
liver of Cre injected mice was completely normal with 
no microscopic lesions (Figure 3D). At 15 to 21 weeks 
post injection, small tumor nodules could be found in Cre 
injected mouse livers (Figure 3D). Histologically, tumors 
were exclusively HB, with frequent Ki67 positive cells 
(Figure 3D).
In summary, the present study demonstrates that 
ablation of Raptor strongly inhibits YAP/β-catenin 
driven HB formation in mice, supporting a major role of 
mTORC1 in HB. 
Figure 3: Knocking out Raptor strongly delays YAP/β-catenin-induced HB development in mice. A. Study design. B. 
Survival curve. C. Liver weight and liver/body weight of YAP/β-catenin/pT3EF1α (pT3) and YAP/β-catenin/pT3EF1α-Cre (Cre) injected 
mice. Data are presented as mean ± SEM. *** P < 0.001; ns, not significant. D. Gross images of livers, HE and Ki67 staining in pT3 and 
Cre mouse livers. Magnifications: 40× (HE), scale bar = 500μm; 200× (Ki67), scale bar = 100μm.
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YAP and TAZ regulate mTOR activation via 
SLC38A1 along HB development
Next, we investigated the possible mechanisms 
whereby mTORC1 is activated in HB. In this regard, 
a recent study suggested that YAP and TAZ regulate 
SLC38A1 and SLC7A5 expression in human HCC 
cells, leading to mTORC1 activation [22]. Therefore, we 
tested the hypothesis that YAP and TAZ may function to 
regulate mTORC1 in an analogous manner in HB. For this 
purpose, we first determined the expression of amino acid 
transporters SLC38A1, SLC7A5, and SLC1A5 in normal 
liver and YAP/β-catenin-induced HB tissues. Connective 
tissue growth factor (CTGF), a well-known target of YAP, 
was used as positive control (Figure 4A). Importantly, we 
found that in YAP/β-catenin-induced HB tumors, only 
SLC38A1 expression was upregulated (Figure 4A). Next, 
we investigated whether amino acids were required for 
human HB cell growth and mTORC1 activation. For this 
purpose, Hep293TT and HepG2 cells were cultured in 
amino acid free medium (Figure 4B and 4C). Of note, we 
found that deprivation of amino acids strongly inhibited 
Hep293TT and HepG2 cell growth (Figure 4B), and it led 
to the reduction of mTORC1 activation, as indicated by 
decreased p-mTOR, p-S6K, p-RPS6, and p-4EBP1 levels 
(Figure 4C). Thus, the results support the hypothesis that 
amino acids are key activators of mTORC1 in HB cells.
We further investigated whether YAP and TAZ 
control mTORC1 activity in HB cells. For this goal, we 
silenced YAP, either alone or in association with TAZ, 
using siRNAs in Hep293TT and HepG2 cells. We found 
that, indeed, when YAP and TAZ were concomitantly 
silenced, p-RPS6 levels were significantly decreased 
(Figure 5A). Next, we determined whether YAP and 
TAZ modulate SLC38A1 expression. Again, YAP alone, 
TAZ alone or YAP and TAZ together were silenced in 
Hep293TT and HepG2 cells. Expression of SLC38A1 
and YAP/TAZ target genes (CTGF and cysteine-rich 61 
or CYR61) was analyzed using qRT-PCR. As expected, 
concomitant silencing of YAP and TAZ triggered 
downregulation of CTGF, CYR61, and SLC38A1 in 
Hep293TT and HepG2 cells (Figure 5B). Finally, using 
chromatin immunoprecipitation (ChIP) assay, we found 
that YAP binds to the promoter region of SLC38A1 
(Figure 5C) in HepG2 and Hep293TT cells, supporting 
the hypothesis that YAP directly regulates SLC38A1 
expression in HB cells.
Table 1: Detailed mouse data from YAP/β-catenin/pT3 EF1α (pT3) and YAP/β-catenin/pT3 EF1α Cre (Cre) injected 
Raptorfl/fl mice
Injection Gender weeks post injection body weight (g) liver weight (g) macroscopic view
YAP/β-catenin/pT3 EF1α
M 9 25.5 5.2 Tumor (whole liver)
M 9.6 27 7.7 Tumor(whole liver)
F 9.8 21.6 4.6 Tumor(whole liver)
F 10.4 21.3 6.1 Tumor(whole liver)
M 10.9 26.3 6.1 Tumor(whole liver)
F 11 24 4.1 Tumor(whole liver)
M 12.3 25.6 5.9 Tumor(whole liver)
YAP/β-catenin/pT3 EF1α Cre
F 10.1 25.2 1.1 Normal liver
M 11 30 1.5 Normal liver
M 11.3 26 1.6 Normal liver
M 12.9 34.1 1.7 Normal liver
M 15.3 34.1 1.7 A nodule(D=1.5mm)
M 17.6 31.5 1.7 Nodule (N=4) 
F 20.3 25.4 1 Normal liver
F 20.7 24.4 1 A nodule (D=1mm)
M 21.3 31.4 1.6 Nodule (N=3)
M 21.3 28.8 3 Nodule (N=8)
Abbreviations: D, diameter; N, number of nodules.
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β-catenin plays no significant role in regulating 
SLC38A1 levels in hepatoblatoma cells
Since YAP synergizes with β-catenin to induce HB 
formation, we next determined whether β-catenin also 
regulates SLC38A1 expression. However, no significant 
changes in SLC38A1 mRNA and protein levels were 
detected in HB cell lines upon β-catenin silencing 
(Figure 6), thus indicating that modulation of SLC38A1 
expression is β-catenin-independent in HB cells. 
mTORC1 signaling and SLC38A1 are 
concomitantly activated in human hepatoblastoma
Finally, we assessed the levels of p-4EBP1, a 
surrogate marker of mTORC1 activation, and SLC38A1 
in a collection of human HB specimens (n = 28) by 
immunohistochemistry (Figure 7). Strikingly, strong 
immunoreactivity for p-4EBP1 and SLC38A1 proteins 
was detected in most tumor tissues when compared with 
corresponding non-tumorous surrounding liver tissues 
(Figure 7). Specifically, increased levels of SLC38A1 
and p-4EBP1 were detected in 20 of 28 (71.4%) and 23 
of 28 (82.1%) HB specimens, respectively. Of note, 18 
of 20 (90%) HB showing upregulation of SLC38A1 also 
displayed elevated levels of p-4EBP1. No significant 
association was found between the levels of SLC38A1 
and/or p-4EBP1 with clinicopathologic features of 
the patients, including age, gender, etiology, histology 
subtype, recurrence or lung metastasis (data not shown).
In summary, our comprehensive studies demonstrate 
that YAP and TAZ positively modulate mTORC1 activity 
via SLC38A1 mediated amino acid uptake and promote 
HB pathogenesis both in human and in mice (Figure 8).
DISCUSSION
HB is a malignant form of liver cancer occurring in 
infants and children [1, 2]. Similar to other tumor types, 
multiple genetic alternations are likely to be required for 
the development of HB. In particular, somatic mutations 
of the CNNTB1 gene leading to the activation of Wnt/β-
catenin signaling cascade, are a well-documented major 
driver genetic event in HB development [4, 5]. A recent 
body of evidence indicates that YAP is another, pivotal 
factor commonly activated in HB [11]. In particular, it has 
been shown that concomitant activation of β-catenin and 
YAP results in HB formation in mice [11]. Also, silencing 
of YAP and/or β-catenin leads to decreased proliferation 
of HB cell lines [11]. However, the precise mechanisms 
by which YAP promotes HB development are not known. 
In this study, we demonstrate that mTORC1 is activated 
in both human HB cell lines and mouse YAP/β-catenin-
induced tumor tissues. The importance of the mTORC1 
pathway along HB development is underscored by the 
finding that inhibition of mTORC1 by either MLN0128 
treatment or ablation of Raptor strongly suppresses HB 
occurrence in mice. Furthermore, we showed that YAP 
and its paralog TAZ regulate the expression of the amino 
acid transporter SLC38A1 in human HB cell lines, leading 
to mTORC1 activation (Figure 8). Our investigation 
therefore provides novel mechanistic insight into how 
YAP and TAZ may contribute to HB formation.
The mTOR pathway is a major signaling cascade 
regulating tumor cell growth and metabolism [12]. 
Thus, targeting the mTOR pathway is considered to 
be a valid therapeutic approach for cancer treatment 
[17]. Studies of mTOR pathway in HB are still scanty. 
Hartmann et al. reported that in 24 human HB specimens, 
p-mTOR expression was detected in 96% (23/24) 
Table 2: Clinicopathological features of hepatoblastoma (HB) patients
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cases [23]. Similarly, in the present study, we show 
the activation of mTORC1 (as revealed by p-4EBP1 
immunohistochemistry) in the large majority of HB 
specimens from an independent collection. In addition, 
it has been found that Rapamycin inhibits proliferation 
and induces apoptosis in HepG2, HepT1, and Huh6 
human HB cells in vitro. Rapamycin also suppresses 
Huh6 growth in a xenograft model [24]. Altogether, these 
data indicate that mTOR, and particularly mTORC1, 
is frequently activated in human HB. Thus, targeting 
mTORC1 might be beneficial for HB treatment. However, 
the mechanisms promoting mTORC1 activation in HB 
were not investigated to date. In our current investigation, 
we provide a novel mechanism by which YAP and TAZ 
activate mTORC1, namely via transcriptional upregulation 
of SLC38A1. In this regard, the concordant data obtained 
in the YAP/β-catenin mouse model, HB cell lines, and 
human HB specimens strongly suggest that the same 
mechanism of mTORC1 induction is at play along 
murine and human HB development. Nonetheless, larger 
human HB collections should be analyzed to further 
substantiate the present findings. Although we found 
that YAP contributes to HB development via activation 
of mTORC1, we cannot exclude that YAP promotes 
HB occurrence also through additional molecular 
mechanisms. For instance, it has been recently shown that 
the transcription factor Forkhead Box M1 (FOXM1) is a 
major player along hepatocellular carcinoma development 
driven by YAP overexpression [25]. Preliminary data from 
our laboratory show that the functional interplay between 
YAP and FOXM1 is also present in human HB cell lines 
(Supplementary Figure 1). Additional investigation is 
required to determine the importance of FOXM1 in YAP-
dependent HB development.
Furthermore, our data suggest the functional 
redundancy of YAP and its paralog TAZ in regulating 
Figure 4: Amino acids are the major factor regulating mTORC1 function in the YAP/β-catenin-induced HB model. 
A. Expression of CTGF, SLC38A1, SLC1A5, and SLC7A5 in wild type (WT) liver and YAP/β-catenin-induced HB by qRT-PCR. Data 
are presented as mean ± SEM. * P < 0.05, ** P < 0.01; ns, not significant. B. Relative cell viability in amino acid deficient (AA-) medium 
compared to that in regular medium (control). C. Western blotting showing that amino acid deprivation inhibits mTORC1 activation in 
HepG2 and Hep293TT cells. 
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SLC38A1 expression and mTORC1 activity in human HB 
cells. While the relevance of YAP in HB is underscored by 
a body of experimental evidence, including the findings 
from the present study, there is no study on the role of 
TAZ in this tumor type. Our results support the possible 
involvement of TAZ in HB, and this issue clearly warrants 
further studies. In particular, it would be highly important 
to determine whether YAP and TAZ, besides SLC38A1 
and mTORC1, regulate the same or distinct pathways in 
HB. 
Solute carrier (SLC) proteins are large families 
of membrane transporters involving multiple cellular 
activities, such as nutrient uptake, waste removal, and 
iron transport [26]. Recent studies have indicated the key 
roles of amino acid transporters along tumor development 
[27], especially in regulating the mTOR pathway [28]. 
For instance, a recent work from our group indicates that 
SLC1A5 and SLC7A6 are direct targets of c-Myc and 
are required for c-Myc induced mTORC1 activation in 
HCC [29]. Also, SLC1A5 mediated glutamine uptake 
was found to be required for lung cancer cell growth 
[30]. The functional roles of amino acid transporters in 
HB formation are not well characterized. In this study, 
we demonstrate that SLC38A1 is regulated by YAP and 
TAZ in HB cells. Unlike YAP and TAZ, which are nuclear 
proteins and are difficult to be targeted by small molecules 
or antibody antagonists, SLC families of transporter 
proteins are clearly druggable. Indeed, SLC targeting 
drugs have been widely used for the treatment of multiple 
diseases, including, central nervous system disorders, 
cardiovascular disease, and antineoplastic treatment [31]. 
Thus, our study supports the development of drugs that 
target SLC38A1 for HB therapy. 
Figure 5: YAP and TAZ activate mTORC1 function via regulating SLC38A1 expression. HepG2 and Hep293TT cells 
were transfected with indicated siRNA for 48-72 hours, siY+T: siYAP+siTAZ. A. Expression of YAP, TAZ and phosphorylated/activated 
(p)-RPS6 were measured by Western blotting. B. qRT-PCR was used to analyze CTGF, CYR61, and SLC38A1 expression. Data are 
presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. C. Direct binding of YAP to SLC38A1 promoter analyzed by chromatin 
immunoprecipitation (ChIP)-PCR in HepG2 and Hep293TT cells.
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Figure 7: Frequent concomitant activation of mTORC1 and SLC38A1 in human hepatoblastoma. Immunohistochemical 
pattern of phosphorylated/inactivated (p-)4EBP1, a surrogate marker of mTORC1 activation, and SLC38A1 in two human hepatoblatoma 
specimens. The two hepatoblastomas A., B. are depicted in two magnifications (40X and 200X; upper and lower panels, respectively) and 
show strong immunoreactivity for both mTORC1 and SLC38A1 in the tumor part (T) when compared with non-tumorous surrounding liver 
tissues (ST). H&E, haematoxylin and eosin staining. 
Figure 6: Genetic disruption of β-catenin does not affect SLC38A1 levels in HB cell lines. SLC38A1 mRNA levels were 
detected following silencing of β-catenin in HepG2 A. and Hep293TT B. cell lines by qRT-PCR. Data are presented as mean ± SEM. *** 
P < 0.001, ns, not significant. No changes in SLC38A1 protein levels were detected in HepG2 C. and Hep293TT D. cell lines following 




The construct used for the mice, including pT3-
EF1α-YAPS127A, pT3-EF1α-ΔN90-β-catenin, pT3-EF1α, 
pT3-EF1α-Cre, and pCMV/sleeping beauty transposase 
(SB), were described previously [11, 21]. All the plasmids 
were purified using the Endotoxin free Maxi prep kit 
(Sigma-Aldrich, St. Louis, MO, USA). 
Mice and hydrodynamic transfection
Wild-type FVB/N mice were obtained from Jackson 
Laboratory (Bar Harbor, ME). Raptorfl/+ mice [32] were 
purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA; stock: 013188) and intercrossed to generate 
Raptorfl/fl mice. SB-mediated hydrodynamic injections 
were performed as described [33]. Briefly, for the HB 
tumorigenesis model, 20 μg of pT3-EF1α-YAPS127A 
and 20 μg of pT3-EF1αH-ΔN90-β-catenin along with 
SB transposase in a ratio of 25:1 were delivered into 
the FVB/N mouse by hydrodynamic injection. These 
two plasmids contain constitutively active forms of YAP 
and β-catenin protooncogenes. For further knocking out 
Raptor in the HB model, either 40μg pT3-EF1a or 40μg 
pT3-EF1a-Cre were co-injected with 20μg pT3-EF1α-
YAPS127A and 20μg pT3-EF1α-ΔN90-beta-catenin 
together as well as 3.2μg pCMV-SB in Raptorfl/fl mice. All 
mice were monitored closely and euthanized as described 
in the main text. Mice were fed and monitored according 
to protocols approved by the Committee for Animal 
Research at the University of California, San Francisco.
Human HB cell lines and in vitro treatments
The Hep293TT cell line [18] was kindly provided 
to us by Dr. Gail Tomlinson from the University of Texas 
Southwestern Medical Center. Hep293TT cells were 
cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium, 25mM Hepes, 10% fetal bovine serum 
(FBS) and 1% penicillin/ streptomycin (Gibco). HepG2 
and SNU449 cells were purchased from ATCC and they 
were cultured in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% FBS and 1% penicillin/ 
streptomycin. To block mTORC1 signaling, MLN0128 
(LC Laboratories), a second generation of mTOR kinase 
inhibitor was diluted to gradient concentration and added 
to the cells. Dimethyl sulfoxide (DMSO) was diluted 
and used as control. After 48 hours treatment, cells were 
stained with crystal violet or collected for protein analysis. 
Cell proliferation and apoptosis were assessed using 
Figure 8: Pathway illustration. YAP and its paralog TAZ regulate the expression of the amino acid transporter SLC38A1, thus leading 
to mTORC1 activation and hepatoblastoma formation.
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the BrdU Cell Proliferation Assay Kit (Cell Signaling 
Technology Inc) and the Cell Death Detection Elisa Plus 
Kit (Roche Molecular Biochemicals, Indianapolis, IN), 
respectively, following the manufacturers’ instructions.
For amino acid deprivation experiments, Amino 
Acid Free Medium (US Biological, Salem, MA) was 
added to the cells. Subsequently, cells were stained 
with crystal violet or collected for protein analysis. For 
gene silencing studies, cells were plated in 6-well plates 
and transfected with 30 pmol siRNA targeting YAP 
(ID# s20366; ThermoFisher Scientific, Waltham, MA), 
TAZ (ID# s24789; ThermoFisher Scientific), TEAD4 
(ID# 107036; ThermoFisher Scientific), and β-catenin 
(ID# AM51331; ThermoFisher Scientific), either alone 
or in combination using Lipofectamine RNAiMAX 
(Life Technologies) according to the manufacturer’s 
instructions. A scramble small interfering RNA (siRNA; 
ID# 4390844; ThermoFisher Scientific) was used as 
negative control RNA. 48-72h post transfection, cells were 
collected for protein and RNA analysis. Experiments were 
repeated at least three times in triplicate.
Chromatin immunoprecipitation assay
Cells were crosslinked in 1% formaldehyde 
(Polysciences, Inc. #18814) for 7 min at room 
temperature. After glycine quenching, cell pellets 
were collected, and sonicated using the Diagenode 
Bioruptor. Sonication was performed at high power, 
30s on, 30s off, 5 min per cycle, for a total of 3 cycles. 
The sheared chromatin was incubated with protein A 
beads (ZYMO Research, Irvine, CA) and antibodies 
(YAP, 14074, Cell Signaling Technology; or Rabbit IgG, 
2729, Cell Signaling Technology). DNA was purified 
using the Zymo-Spin ChIP Kit (D5210) and quantified 
by PCR. The primer sequences used for PCR were: 
human SLC38A1 promoter region primer forward (F): 
5’- CAAGATTTGGATGTGCCACTTAG -3’; human 
SLC38A1 promoter region primer reverse (R): 5’- 
TGATTCCTCTATTCACTGTGTGCT-3’.
Protein extraction and Western blotting
Liver tissues or cell pellets were homogenized or 
suspended in lysis buffer [30 mM Tris (pH 7.5), 150 mM 
NaCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, 
10% glycerol, and 2mM EDTA] containing the Complete 
Protease Inhibitor Cocktail (ThermoFisher Scientific). 
Protein concentrations were determined with the Bio-
Rad Protein Assay Kit (Bio-Rad, Hercules, CA) using 
bovine serum albumin as a standard. Aliquots of 30 μg 
lysates were denatured by boiling in Tris-Glycine SDS 
Sample Buffer (Bio-Rad), separated by SDS-PAGE, and 
transferred to nitrocellulose membranes (Bio-Rad) by 
electroblotting. Membranes were blocked in 5% non-
fat dry milk in Tris-buffered saline containing 0.1% 
Tween 20 for 1 hour and probed with following specific 
antibodies: AKT (9272), Phospho-AKT(S473) (4060), 
Phospho-AKT(T308) (13038), Phospho-mTOR (2971), 
Phospho-p70 S6 Kinase (9205), Phospho-RPS6 (4858), 
Phospho-4E-BP1(T37/46) (2855), Phospho-4E-BP1(S65) 
(9451), Phospho-NDRG1 (5482), Survivin (2808), YAP/
TAZ (8418), Cleaved Caspase-3 (CC-3) (9664), Mcl-
1 (94296), Bcl-Xl (2764), Bak (12105; Cell Signaling 
Technology), SLC38A1 (HPA052272; Sigma-Aldrich, 
St. Louis, MO). Anti-β-catenin antibody (610153) was 
purchased from BD Biosciences (Franklin Lakes, NJ). 
Anti-GAPDH (MAB374; EMD Millipore, Billerica, MA), 
anti-β-Actin (A5441; Sigma-Aldrich, St. Louis, MO), and 
anti-β-tubulin (6046; Abcam) antibodies were used as 
loading controls. Each primary antibody was followed 
by incubation with horseradish peroxidase-secondary 
antibody (Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA) diluted 1:10000 for 1 hour and then 
visualized by the Super Signal West Dura (ThermoFisher 
Scientific). For nuclear protein extraction, proteins were 
extracted by using the Cytoplasmic Extraction Reagent 
I and II (ThermoFisher Scientific). After thoroughly 
removing the supernatant (cytoplasmic extract), Nuclear 
Extraction Reagent (ThermoFisher Scientific) was added 
for the nuclear protein extraction. Aliquots of 5-10 μg of 
nuclear and cytoplasmic lysates were used for Western 
blotting. Isolation of cytoplasmic proteins was validated 
by β-tubulin, while Histone H3 (D1H2) (4499; Cell 
Signaling Technology) was used as loading control of 
nuclear proteins.
Quantitative reverse transcription real-time 
polymerase chain reaction (qRT-PCR)
qRT-PCR reactions were performed with 100 
ng of cDNA on the whole sample collection and cell 
lines, using an ABI Prism 7000 Sequence Detection 
System and TaqMan Universal PCR Master Mix 
(ThermoFisher Scientific). Reaction conditions were: 10 
min of denaturation at 95°C and 40 cycles at 95°C for 
15 s and at 60°C for 1 min. Quantitative values were 
calculated by the PE Biosystems Analysis software and 
expressed as N target (NT). NT = 2-ΔCt, wherein ΔCt 
value of each sample was calculated by subtracting the 
average Ct value of the target gene from the average 
Ct value of the ribosomal RNA (rRNA) gene. Primers 
used in the study include: 18S rRNA Forward (F): 
5’-CGGCTACCACATCCAAGGAA-3’, Reverse 
(R): 5’-GCTGGAATTACCGCGGCT-3’; Mouse 
CTGF: F: 5’-GGGCCTCTTCTGCGATTTC-3’, R: 5’- 
ATCCAGGCAAGTGCATTGGTA-3’; Mouse SLC38A1: 
F: 5′-AGCAACGACTCTAATGACTTCAC-3’, R: 
5’-CCTCCTACTCTCCCGATCTGA-3’; Mouse 
SLC7A5: F: 5′-CTACGCCTACATGCTGGAGG-3’, 
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R: 5’-GAGGGCCGAATGATGAGCAG-3’; Mouse 
SLC1A5: F: 5′-TTCGCTATCGTCTTTGGTGTG-3’, 
R: 5’-ATGGTGGCATCATTGAAGGAG-3’; Human 
CTGF: F: 5′-CAGCATGGACGTTCGTCTG-3’, 
R: 5’-AACCACGGTTTGGTCCTTGG-3’; Human 
CYR61: F: 5′-GGTCAAAGTTACCGGGCAGT-3’, 
R: 5’-GGAGGCATCGAATCCCAGC-3’; Human 
SLC38A1: F: 5′-AACCTCCTTAGGCATGTCTGT-3’, 
R: 5’-GCAAAGGCGAGTCCCAAAAT-3’; Human 
YAP1: F: 5’-TAGCCCTGCGTAGCCAGTTA-3’, R: 
5’-TCATGCTTAGTCCACTGTCTGT-3’; Human 
TEAD4: F: 5’-GGACACTACTCTTACCGCATCC-3’, 
R: 5’-TCAAAGACATAGGCAATGCACA-3’; Human 
FOXM1: F: 5’-TTGCCCGAGCACTTGGAATC-3’, 
R: 5’-GTATGAGCTGACCCGTGGT-3’. Predesigned 
primers for human β-catenin (ID# Hs00355049_m1) were 
purchased from Applied Biosystems (Foster City, CA).
Immunohistochemistry
Liver specimens were fixed in 4% paraformaldehyde 
overnight at 4°C and embedded in paraffin. Hematoxylin 
& Eosin (H&E) staining on 4μm liver sections 
was performed to characterize histopathologically 
liver preneoplastic and neoplastic lesions in mice. 
Immunohistochemistry was performed as described 
previously [29]. Briefly, antigen retrieval was achieved in 
deparaffinized sections by boiling in 10mM sodium citrate 
buffer (pH 6.0) for 10 min. After a blocking step with the 
5% goat serum and Avidin-Biotin blocking kit (Vector 
Laboratories, Burlingame, CA), the slides were incubated 
with primary antibodies overnight at 4°C. Primary 
antibodies used for the experiment are as follows: p-RPS6 
(4858; Cell Signaling Technology), Ki67 (RM-9106; 
Thermo Fisher Scientific), p-4EBP1 (2855; Cell Signaling 
Technology), and SLC38A1 (HPA052272; Sigma-
Aldrich, St. Louis, MO). These primary antibodies were 
selected for the analysis since they have been extensively 
validated by the manufacturers for immunohistochemistry. 
After washes, slides were incubated in 3% H2O2 for 20 
minutes to quench the endogenous peroxidase, then 
followed by one hour of secondary antibody incubation. 
Signal was detected by the Vectastain ABC Elite Kit 
(Vector Laboratories) and visualized by DAB (Vector 
Laboratories). 
Human tissue samples
A collection of formalin-fixed, paraffin-embedded 
human HB (n = 28) samples was used in the present study. 
The clinicopathological features of liver cancer patients 
are summarized in Table 2. HB specimens were collected 
at the Medical University of Greifswald (Greifswald, 
Germany) and from the Archives of the Pathology 
Departments of Semmelweis University (Budapest, 
Hungary). Institutional Review Board approval was 
obtained at the local Ethical Committee of the Medical 
University of Greifswald and the Regional Ethical 
Committee of the Semmelweis University. Informed 
consent was obtained from all subjects.
Statistical analysis
All data are presented as mean ± SEM. Statistical 
analysis was performed using two-tailed unpaired t test 
or Tukey-Kramer test. P value < 0.05 was considered 
significant. Overall survival was estimated according 
to Kaplan-Meier and Log-rank (Mantel-Cox) test. All 
statistics were performed with Prism 6, version 6.0 
(GraphPad Software Inc., La Jolla, CA). 
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